Columbia University Medical Center/NewYork Presbyterian Hospital, New York, New York.
Columbia University Medical Center/NewYork Presbyterian Hospital, New York, New York.
JACC Cardiovasc Imaging. 2019 Mar;12(3):416-429. doi: 10.1016/j.jcmg.2018.08.034. Epub 2018 Dec 12.
OBJECTIVES: This study presents a single-site experience of 5 patients with severe tricuspid regurgitation (TR) who underwent implantation of a novel transcatheter tricuspid valve replacement device. BACKGROUND: Functional TR is the most common etiology of severe TR in the developed world and is associated with unfavorable clinical outcomes. Although numerous transcatheter repair devices are currently in early clinical trials, most result in incomplete degrees of TR reduction and functional improvement. METHODS: Transcatheter tricuspid valve replacement was performed in 5 patients with compassionate use of the novel GATE System. All patients had symptomatic, massive and/or torrential TR at baseline. All patients had computed tomography, transthoracic and transesophageal echocardiographic assessment of the tricuspid valve and right heart anatomy. All patients had a surgical transatrial approach performed with valve implantation guided by fluoroscopy and intraprocedural transesophageal echocardiography. RESULTS: Baseline characteristics of the patients showed a substantial burden of comorbidities. All patients had successful implantation of the transcatheter valve, with significant reduction of TR to ≤2+. Baseline poor right ventricular (RV) function measured by global longitudinal strain and RV change in pressure divided by change in time were associated with post-implantation RV failure and poor clinical outcomes in this small group. Four of the 5 patients were followed for 3 to 6 months following the initial implantation and showed evidence of RV remodeling, increased cardiac output, and reduction in New York Heart Association functional class. CONCLUSIONS: Implantation of a first-generation TTVR device was technically feasible in patients with more than severe TR. Transcatheter tricuspid valve replacement was associated with RV remodeling, increased cardiac output, and improvement in New York Heart Association functional class in most patients. Further studies are needed to refine patient population selection for this device and to determine long-term outcomes.
目的:本研究报告了 5 例严重三尖瓣反流(TR)患者在单一中心接受新型经导管三尖瓣置换装置植入的经验。
背景:功能性 TR 是发达国家最常见的严重 TR 病因,与不良临床结局相关。尽管目前有许多经导管修复装置处于早期临床试验阶段,但大多数装置只能部分减轻 TR 程度并改善功能。
方法:5 例患者因同情使用新型 GATE 系统而接受经导管三尖瓣置换术。所有患者在基线时均有症状性、大量和/或 torrential TR。所有患者均进行了计算机断层扫描、经胸超声心动图和经食管超声心动图评估三尖瓣和右心解剖结构。所有患者均采用经心房入路进行手术,并在透视和术中经食管超声心动图的引导下植入瓣膜。
结果:患者的基线特征显示出大量合并症的负担。所有患者均成功植入了经导管瓣膜,TR 显著降低至≤2+。通过整体纵向应变和 RV 压力变化除以时间变化来衡量的基线较差的右心室(RV)功能与植入后 RV 衰竭和该小群体不良临床结局相关。5 例患者中的 4 例在初始植入后随访 3 至 6 个月,显示 RV 重塑、心输出量增加和纽约心脏协会功能分级降低的证据。
结论:在存在严重以上 TR 的患者中,植入第一代 TTVR 装置在技术上是可行的。在大多数患者中,经导管三尖瓣置换术与 RV 重塑、心输出量增加和纽约心脏协会功能分级改善相关。需要进一步的研究来细化该装置的患者人群选择,并确定长期结果。
JACC Cardiovasc Imaging. 2018-12-12
JACC Cardiovasc Interv. 2017-10-9
JACC Cardiovasc Interv. 2019-8-12
Ann Med Surg (Lond). 2025-5-30
Struct Heart. 2025-5-30
Rev Cardiovasc Med. 2025-3-5
US Cardiol. 2021-6-30